Lantheus Medical Imaging Announces Strategic Hires to Core Business Areas
Company Continues Growth with Key Appointments to Management Staff
N. BILLERICA, Mass. (Nov. 4, 2008) - Lantheus Medical Imaging, a worldwide leader in diagnostic imaging, announced today the appointment of four strategic new hires to core business functions. Key Lantheus appointments include: David Pendleton as senior director, PET Perfusion Agent; Alexander Ehlgen, M.D., Ph.D. as associate medical director, DEFINITY®; Daniel Griffin as director, compensation and benefits; and Erin Boyer as senior business partner and director, human resources. Lantheus has nearly 700 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada, and Australia.
“The appointment of these industry leaders reflects our continued growth and commitment to fostering a culture of innovation and attracting employees who are passionate and dedicated to developing new tools for the diagnosis and management of disease,” said Philip Lockwood, vice president, human resources of Lantheus Medical Imaging. “We are thrilled to welcome these esteemed colleagues to Lantheus and look forward to leveraging their deep experience in the medical imaging and diagnostics space.”
David Pendleton, a veteran in the medical imaging industry, has been named senior director, PET perfusion agent. Mr. Pendleton joins Lantheus from CHS Consulting where he engaged with a wide variety of therapeutic and diagnostic imaging companies in areas including business development, strategic marketing, marketing management and launch planning. Prior to CHS he served as director of marketing and clinical operations for Theseus Imaging. From 1981 to 2002, Mr. Pendleton held several positions at DuPont Pharmaceuticals including senior marketing director of DEFINITY®, and he was the brand director of Cardiolite® prior to the company’s acquisition by Bristol-Myers Squibb in 2001. He received his B.S. in biology from Northeastern University.
Alexander Ehlgen, M.D., Ph.D., joins Lantheus as associate medical director, DEFINITY®. Prior to joining Lantheus, Dr. Ehlgen served as senior director of clinical affairs for start-up biotechnology company POINT Biomedical Corporation. In this position, he was responsible for the clinical development of an ultrasound imaging agent to diagnose coronary artery disease. He was a postdoctoral research fellow for the University of Oxford’s John Radcliffe Hospital and Medical Vision Laboratory. Dr. Ehlgen received his M.D. and Ph.D. from the University of Bonn in Germany and has been published in more than 20 scientific and medical journals.
Daniel Griffin joins Lantheus as director, compensation and benefits from Novartis Vaccines and Diagnostics, where he served as director, U.S. compensation and benefits. At Novartis Vaccines and Diagnostics, he led the transition from the Chiron Corporation compensation programs to the Novartis structure and refined the company’s competitive positioning, implemented vendor and program changes, helped formulate Novartis’ long-term U.S. corporate benefits strategy and contributed to the founding of the new global leadership center. Prior to Novartis, Mr. Griffin was the compensation director for Biogen Idec for seven years, and the compensation and benefits director for Hadco Corporation. Mr. Griffin received his M.B.A. from Bentley College and a B.S. in business administration from Northeastern University.
Erin Boyer brings more than 10 years of human resources management experience to Lantheus as the new senior business partner and director, human resources. During her time at Dyax Corporation as the director of human resources, Ms. Boyer was responsible for administration, benefits and compensation, performance management, employee relations and recruiting. Prior to joining Dyax, she held various human resources management positions at Nuance Inc. and Avicon, Inc. Ms. Boyer received her B.A. degree in history from Macalester College.
About Lantheus Medical Imaging
Lantheus Medical Imaging, a worldwide leader in diagnostic medicine for the past 50 years, is committed to advancing the field of diagnostic imaging. The company’s proven success in discovering, developing and marketing innovative medical imaging agents provides an unparalleled platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. The company is home to leading diagnostic imaging brands, including Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, and TechneLite® (Technetium Tc99m Generator) and has nearly 700 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada, and Australia. For more information, visit www.lantheus.com.